| http://www.w3.org/ns/prov#value | - In particular, Example 14 and FIGS. 25-29 show that systemic intraperitoneal delivery of a CLK inhibitor leads to a decrease in body weight, a decrease in blood insulin levels, and a decrease in blood glucose levels, all of which would be beneficial for the treatment of diabetes or other metabolic diseases and disorders.
|
